Neurological phenomenology of the IRF2BPL mutation syndrome: Analysis of a new case and systematic review of the literature.


Journal

Seizure
ISSN: 1532-2688
Titre abrégé: Seizure
Pays: England
ID NLM: 9306979

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 30 11 2021
revised: 01 04 2022
accepted: 16 04 2022
pubmed: 8 5 2022
medline: 16 6 2022
entrez: 7 5 2022
Statut: ppublish

Résumé

IRF2BPL is an intronless gene that was mapped to 14q24.3 chromosome in 2000 and codes for the interferon regulatory factor 2 binding like protein. To analyses the clinical characteristics of the patients reported in the literature and of an additional patient we observed in order to better delineate the phenomenological spectrum of the disease and provide indications to improve clinical recognition and facilitate diagnosis. We reported on 28 patients carrying the IRF2BPL mutation who were identified in 10 papers (n.27), using PUBMED as the search engine, and in our hospital (n. 1). All patients shared developmental delay/regression. Additional neurological symptoms were present in a large proportion of patients and reflected the involvement of five main neurological domains, i.e. epilepsy, dystonia, ataxia, spasticity, and ocular disturbances. Correlation analysis suggested a significant positive correlation between the number of affected neurological domains and the presence of MRI abnormalities (rho = 0.45, p = 0.02), while no significant correlation emerged between the number of affected clinical domains and age at disease onset (rho = 0.18, p = 0.35) or variant type (rho = 0.30, p = 0.12). Our analysis highlights that the IRF2BPL mutation syndrome is highly specific to the central nervous system. Diagnostic work-up should consider the clinical picture of the IRF2BPL mutation syndrome herein delineated and the existence of conditions that share developmental delay/regression and result from acquired/genetic or unidentifiable underlying etiology.

Sections du résumé

BACKGROUND BACKGROUND
IRF2BPL is an intronless gene that was mapped to 14q24.3 chromosome in 2000 and codes for the interferon regulatory factor 2 binding like protein.
OBJECTIVE OBJECTIVE
To analyses the clinical characteristics of the patients reported in the literature and of an additional patient we observed in order to better delineate the phenomenological spectrum of the disease and provide indications to improve clinical recognition and facilitate diagnosis.
METHODS METHODS
We reported on 28 patients carrying the IRF2BPL mutation who were identified in 10 papers (n.27), using PUBMED as the search engine, and in our hospital (n. 1).
RESULTS RESULTS
All patients shared developmental delay/regression. Additional neurological symptoms were present in a large proportion of patients and reflected the involvement of five main neurological domains, i.e. epilepsy, dystonia, ataxia, spasticity, and ocular disturbances. Correlation analysis suggested a significant positive correlation between the number of affected neurological domains and the presence of MRI abnormalities (rho = 0.45, p = 0.02), while no significant correlation emerged between the number of affected clinical domains and age at disease onset (rho = 0.18, p = 0.35) or variant type (rho = 0.30, p = 0.12).
CONCLUSIONS CONCLUSIONS
Our analysis highlights that the IRF2BPL mutation syndrome is highly specific to the central nervous system. Diagnostic work-up should consider the clinical picture of the IRF2BPL mutation syndrome herein delineated and the existence of conditions that share developmental delay/regression and result from acquired/genetic or unidentifiable underlying etiology.

Identifiants

pubmed: 35525099
pii: S1059-1311(22)00091-7
doi: 10.1016/j.seizure.2022.04.010
pii:
doi:

Substances chimiques

Carrier Proteins 0
IRF2BPL protein, human 0
Nuclear Proteins 0

Types de publication

Case Reports Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-15

Informations de copyright

Copyright © 2022 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Auteurs

S Pisano (S)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

M Melis (M)

Neurology Unit, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy.

M Figorilli (M)

Neurology Unit, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy.

L Polizzi (L)

Neurology Unit, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy.

L Rocchi (L)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; Neurology Unit, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy.

S Giglio (S)

Medical Genetics Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

G Defazio (G)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; Neurology Unit, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy.

A Muroni (A)

Neurology Unit, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH